(NDRA) ENDRA Life Sciences Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NDRA) ENDRA Life Sciences Inc. Complete Analysis Pack
ENDRA Life Sciences Business Model Canvas: Strategy in Focus
Explore the ENDRA Life Sciences Inc. Business Model Canvas to see how this medtech innovator creates value, builds partnerships, and positions itself in a fast-moving market. This concise, company-specific breakdown helps you understand the key drivers behind its strategy and growth potential. Get the full canvas for a deeper, ready-to-use view of the business.
Partnerships
General Electric collaboration
ENDRA Life Sciences Inc. has a research collaboration agreement with General Electric Company that helps advance technology development and imaging validation. The tie also places ENDRA inside a large medical technology ecosystem, which can speed testing and credibility as it builds ultrasound-based imaging tools.
Clinical study sites
Hospitals and academic medical centers are key because ENDRA Life Sciences Inc.'s thermo-acoustic ultrasound needs real-patient validation across liver disease, ablation monitoring, vascular imaging, and perfusion. Clinical sites also give physician feedback to refine protocols; with liver disease affecting about 30% of adults worldwide, these partners help ENDRA prove utility where the need is largest.
Component suppliers
ENDRA Life Sciences Inc. relies on component suppliers for electronics, transducers, and acoustic parts that keep its ultrasound hardware working; in its 2025 filings, the Company remained pre-revenue, so these vendors are critical for prototype builds, device reliability, and any future scale-up.
Without stable outside supply, manufacturing would be harder and slower, especially for a small Company with limited cash and no product sales yet.
Regulatory and quality advisors
ENDRA Life Sciences Inc. relies on regulatory and quality advisors because medical imaging products must clear FDA review and quality-system rules. The FDA’s Quality Management System Regulation update aligns with ISO 13485 and takes effect on Feb. 2, 2026, so outside experts help with submissions, trial design, and compliance work that cuts risk and speeds commercialization.
- FDA and QMS expertise
- Supports submissions and trials
- Readies products faster
Commercialization partners
ENDRA Life Sciences Inc.'s commercialization partners can extend reach into hospitals and imaging centers far faster than a small direct-sales team. In FY2025, with no broad in-house field force, OEM and distribution deals can also cover installation, training, and service across more sites.
- Expand hospital and imaging-center access
- Reduce direct-sales headcount needs
- Support install, training, and service
ENDRA’s Key Partners Keep Its Ultrasound Platform Moving Forward
ENDRA Life Sciences Inc. depends on General Electric Company, clinical sites, suppliers, and FDA/QMS advisors to validate its thermo-acoustic ultrasound and keep prototypes moving. In FY2025, the Company remained pre-revenue, so these partners were still critical for testing, compliance, and scale-up.
| Partner | Role | FY2025 relevance |
|---|---|---|
| General Electric Company | R&D and imaging validation | Speeds testing and credibility |
| Hospitals | Clinical validation | Supports patient-based proof |
| FDA/QMS advisors | Regulatory support | Aids Feb. 2, 2026 QMSR prep |
What is included in the product
Detailed Word Document
A concise Business Model Canvas capturing ENDRA Life Sciences Inc.’s ultrasound-based medical technology strategy, customers, channels, and value proposition.
Customizable Excel Spreadsheet
Quickly clarifies ENDRA Life Sciences’ business model pain points in one editable, one-page snapshot.
Reference Sources
Provides a credible reference trail for ENDRA Life Sciences Inc. that strengthens trust, speeds diligence, and supports better decisions.
Activities
Thermo-acoustic R and D
ENDRA Life Sciences’ key activity is Thermo-acoustic R and D, where it advances thermo-acoustic enhanced ultrasound to turn sound-wave and thermal sensing into better diagnostic imaging. This work is the core of the TAEUS platform, and it drives the company’s technical progress toward non-invasive imaging use cases.
Clinical validation
Clinical validation is ENDRA Life Sciences Inc.'s key gate for TAEUS in NAFLD, a condition that affects about 1 in 3 adults worldwide, and for related imaging uses. It also must show reliable temperature monitoring during thermoablative procedures, because physicians and hospitals usually adopt only after strong clinical evidence, not just lab results.
Prototype design and testing
ENDRA Life Sciences Inc.’s engineering teams design, build, and test ultrasound systems and software for its TAEUS platform, with bench tests checking image quality, thermal response, and workflow performance before release. The company still needs repeated iteration at the prototype stage, since even small changes in hardware or code can affect imaging consistency and clinical usability.
Regulatory preparation
ENDRA Life Sciences Inc. must keep regulatory preparation tight: build device-file documentation, validate quality systems, and package test and clinical evidence for review and clearance. Regulatory readiness is a core milestone because it gates device progress and future commercialization.
- Quality system documentation
- Test and verification records
- Clinical evidence package
- Clearance readiness milestone
IP and scientific development
ENDRA Life Sciences Inc. depends on patent protection and technical know-how to defend its thermoacoustic imaging platform. It also needs publications, presentations, and validated data packages to prove performance, build partner trust, and support future sales.
- Protect core IP
- Publish credible data
- Support partnering talks
- Enable future sales
ENDRA’s TAEUS Pushes Toward NAFLD Validation and Partnering
ENDRA Life Sciences Inc. is focused on advancing TAEUS through R and D, prototype testing, and clinical validation, with NAFLD still the main target use case. It also must keep regulatory files, quality records, and IP protection tight so the platform can move from lab proof to clearance and partnering.
| Key activity | Why it matters | Data point |
|---|---|---|
| Clinical validation | Proves use in NAFLD | NAFLD affects about 1 in 3 adults |
Delivered as Displayed
Business Model Canvas
This ENDRA Life Sciences Inc. Business Model Canvas preview is the actual document you’ll receive after purchase, not a sample or mockup. What you see here is a direct snapshot of the final file, with the same structure, content, and formatting. Once your order is complete, you’ll get instant access to this exact document for editing, presenting, or sharing.
Resources
Thermo-acoustic platform
ENDRA Life Sciences Inc.’s thermo-acoustic platform is the core resource behind its thermo-acoustic enhanced ultrasound, built to improve diagnostic imaging by combining ultrasound with thermal sensing. This single platform drives the product roadmap and, in FY2025, remained the company’s key technology asset as it pushed toward clinical and commercial validation.
Patent and know-how base
ENDRA Life Sciences Inc. relies on a patent and know-how base to protect its imaging and thermal detection methods, which can strengthen licensing value and barrier to entry. Its proprietary IP helps defend the technology stack and can support a competitive edge in medical imaging markets where protected methods often drive long-term value.
GE collaboration
The General Electric collaboration gives ENDRA Life Sciences Inc. external technical and research support and ties it to a major medical-imaging partner, which can help validate its thermoacoustic ultrasound work. That kind of backing matters for investor and clinical credibility, especially when a company is still pre-scale and needs proof that its tech can fit real hospital workflows.
Technical team
ENDRA Life Sciences Inc. depends on a small technical team with engineering, clinical, and regulatory know-how to build its ultrasound-based imaging platform. The work needs people who understand ultrasound physics, device design, and clinical workflows, because human capital is a core resource in a regulated medtech company.
- Ultrasound physics
- Device design
- Clinical workflows
- Regulatory approval
Corporate headquarters in Ann Arbor
ENDRA Life Sciences Inc. keeps its corporate headquarters in Ann Arbor, Michigan, where the site anchors management, engineering, and admin work. This one base supports company-wide development and coordination, making it the main operating hub for a 1-site headquarters setup.
- Ann Arbor, Michigan headquarters
- Supports management and engineering
- Main base for coordination
ENDRA Life Sciences’ FY2025 Core Assets: Platform, IP, and GE Backing
ENDRA Life Sciences Inc.’s key resources in FY2025 were its thermo-acoustic imaging platform, protected IP, and the technical know-how needed to advance ultrasound-plus-thermal sensing. The General Electric collaboration and Ann Arbor, Michigan headquarters also supported development, validation, and coordination.
| Resource | FY2025 role |
|---|---|
| Thermo-acoustic platform | Core R&D asset |
| IP portfolio | Barrier to entry |
| GE collaboration | External validation |
| Ann Arbor HQ | Management hub |
Value Propositions
Noninvasive liver fat assessment
ENDRA Life Sciences targets the large NAFLD market, which affects about 1 in 4 adults worldwide, with a noninvasive liver fat test that is faster and radiation-free versus MRI or CT-based workflows. That makes it useful for screening and repeat monitoring, where low cost and speed matter most.
Real-time thermal monitoring
ENDRA Life Sciences Inc.'s real-time thermal monitoring helps clinicians track tissue temperature during thermoablative procedures, so treatment can be delivered more precisely and safely. As a pre-commercial platform in fiscal 2025, the value sits in solving a high-stakes interventional workflow need where better temperature control can reduce risk and improve consistency.
Vascular and perfusion imaging
ENDRA Life Sciences’ ultrasound platform targets vascular imaging and tissue perfusion, helping assess blood flow and tissue health with more detail than liver-only use cases. That matters in a market where global ultrasound spending is already in the tens of billions of dollars, and it gives Company Name a broader clinical path than hepatology alone.
Portable ultrasound-based imaging
ENDRA Life Sciences Inc.’s portable ultrasound-based imaging targets faster, lower-cost access than CT or MRI; portable systems can be used at the bedside and in outpatient care, while CT and MRI often cost about $300,000+ and $1 million+, respectively. That makes point-of-care use practical when speed and reach matter.
- Lower capex than CT/MRI
- Bedside, point-of-care use
- Faster clinical decisions
- Broader outpatient access
For hospitals and clinics, this can help expand imaging access without the space, staffing, and workflow burden of larger scanners.
Lower-cost radiation-free option
ENDRA Life Sciences Inc. positions ultrasound as a lower-cost, radiation-free option because it avoids ionizing radiation and can support repeat use without the exposure trade-off. In imaging markets where CT can cost about $200-$1,000 per scan in the U.S., lower-priced ultrasound can widen access and improve follow-up use.
That value proposition matters for broader screening and monitoring, especially where cost or radiation limits repeat imaging. ENDRA Life Sciences Inc. is betting that safer, cheaper imaging can pull more exams into routine care.
- Radiation-free imaging lowers patient risk
- Lower cost can expand access
- Repeat use fits monitoring workflows
ENDRA’s Low-Cost Ultrasound Targets Liver Fat Screening and Thermal Control
ENDRA Life Sciences Inc. offers radiation-free, low-cost ultrasound imaging for liver fat screening and repeat monitoring, targeting NAFLD’s roughly 1 in 4 adults worldwide. It also adds real-time thermal monitoring for ablation procedures, where tighter temperature control can improve safety and consistency.
| Use case | Key value | Number |
|---|---|---|
| NAFLD screening | Noninvasive, repeatable | 1 in 4 adults |
| Imaging cost | Lower than CT/MRI | $200-$1,000 vs $300,000+/$1 million+ |
| Thermal monitoring | Procedure control | Fiscal 2025 pre-commercial |
Customer Relationships
Consultative hospital selling
ENDRA Life Sciences Inc. needs direct, consultative selling with hospitals and imaging departments because buyers expect clinical proof, workflow fit, and ongoing support, not a simple product pitch. In medical devices, solution selling matters more than transaction selling, since each site may need training, integration, and evidence before adoption.
Clinical training support
ENDRA’s customer relationship here is hands-on clinical training: physicians, technologists, and staff must be onboarded on setup, use protocols, and image interpretation for adoption to stick. That support lowers installation and evaluation friction, which matters for a pre-revenue platform still proving clinical workflow fit.
Co-development with clinicians
ENDRA Life Sciences Inc. uses co-development with clinicians so key opinion leaders and clinical investigators can refine product requirements, imaging performance, and real-world workflow. In medtech, that loop matters because ENDRA Life Sciences Inc. is still building adoption in a pre-commercial market, where clinician feedback can make or break usability and trial design.
Technical service and support
ENDRA Life Sciences Inc. must make technical service and support a core Customer Relationships layer because customers of hardware imaging tools expect help with installation, troubleshooting, and maintenance. As a pre-commercial medical device company, strong support builds trust, speeds adoption, and helps retain early users when field issues can slow use.
- Installation help lowers setup friction
- Troubleshooting protects device uptime
- Maintenance support builds long-term trust
Pilot and evaluation programs
ENDRA Life Sciences Inc. uses pilot deployments and study participation as its main customer link, since early hospital users need evidence before adoption. The latest public filings do not show scaled 2025/2026 product revenue, so these programs still act as the proof point and reference-site engine for clinical trust.
- Pilot use builds clinical evidence
- Reference sites support later sales
- Hospitals adopt after study results
ENDRA’s Growth Still Depends on Hands-On Training and Pilot Support
ENDRA Life Sciences Inc. relies on high-touch customer relationships: clinical training, workflow support, and troubleshooting for hospitals, imaging teams, and investigators. This matters because the company still depends on pilots and reference sites, with no scaled product revenue disclosed in its latest public filings through 2025.
| Customer link | Why it matters | 2025/2026 signal |
|---|---|---|
| Training | Drives adoption | Pilot-based |
| Support | Protects uptime | Pre-scale |
| Clinician feedback | Refines workflow | Pre-commercial |
Channels
Direct field sales
ENDRA Life Sciences Inc. uses direct field sales to reach hospitals and clinics, where buyers expect live demos, procurement talks, and install planning; in capital equipment medtech, sales cycles often run 6 to 18 months, so this channel fits long, high-touch deals.
Clinical trial networks
Clinical trial networks are ENDRA Life Sciences Inc.'s early channel to build awareness: study sites and investigator groups can validate the technology, generate clinical data, and create visible reference users before full commercialization. For a clinical-stage Company with no broad sales base yet, these relationships matter more than paid marketing.
Medical conferences
Medical conferences let ENDRA Life Sciences Inc. show data directly to physicians and researchers, which helps build awareness, early validation, and leads for an emerging imaging platform. These meetings are often where first adoption signals form, especially before broad commercial scale.
In practice, one strong conference presentation can reach dozens to hundreds of specialty attendees at once, making it a low-cost way to test clinical interest and refine the message.
Distributor and OEM partners
Distributor and OEM partners let ENDRA Life Sciences reach a much wider hospital base without building a large direct sales team. The U.S. has about 6,100 hospitals, so even a few regional partners can cover more sites, handle service and integration, and keep fixed selling costs low.
- Expands hospital reach fast
- Uses partner sales and service
- Lowers internal overhead needs
Digital clinical outreach
ENDRA Life Sciences Inc. uses websites, webinars, and digital decks to explain thermal imaging and clinical use cases to clinicians and investors. In medtech, 73% of B2B buyers prefer digital self-service first, so these channels can lift meeting requests and trial interest fast.
- Educates clinicians on the technology.
- Builds trust with investors.
- Drives demo and trial requests.
ENDRA’s Go-to-Market Mix Is Built for Long Medtech Sales Cycles
ENDRA Life Sciences Inc. mainly sells through direct field reps, trial-site networks, conferences, partners, and digital outreach, since its imaging platform needs clinical proof and long buyer education cycles. For capital medtech, this mix helps it reach hospitals without building a huge sales force.
| Channel | Use | Data |
|---|---|---|
| Direct sales | Hospital demos | 6-18 month cycles |
| Partners | Broader reach | About 6,100 U.S. hospitals |
| Digital | Lead gen | 73% prefer self-service |
Customer Segments
Hospitals and health systems
Hospitals and integrated health systems are ENDRA Life Sciences Inc.'s main imaging buyers, since they fund tools for liver disease, intervention, and vascular work. With liver disease affecting about 1 in 3 adults worldwide, budget holders judge each purchase by clinical utility and reimbursement, not just price.
Radiology departments
Radiology departments are a natural fit for ENDRA Life Sciences Inc. because they already use imaging for diagnosis and procedure guidance. In large hospital systems, imaging volumes often run into hundreds of studies a month per site, so buyers focus on image quality, workflow speed, and patient throughput when evaluating ultrasound-based platforms.
Hepatology and gastroenterology clinics
Hepatology and gastroenterology clinics are a core customer segment because they manage the large MASLD and fatty liver disease pool, which affects about 30% of adults worldwide. These clinics need repeatable, low-friction monitoring for noninvasive liver assessment, since follow-up imaging and fibrosis checks are routine and often done multiple times a year.
Interventional surgery and oncology teams
Interventional surgery and oncology teams performing thermoablation need real-time temperature monitoring and imaging guidance to control tissue destruction and protect nearby healthy tissue. ENDRA Life Sciences Inc.’s platform fits this workflow because it supports procedure control and safety decisions where live feedback matters most.
- Real-time guidance lowers safety risk
- Best fit: thermoablation procedures
- Values instant procedure control data
Academic medical centers and researchers
Academic medical centers and researchers are often the first to test new imaging tools, so they can give ENDRA Life Sciences Inc. early clinical proof, protocol input, and publishable data. That matters more because ENDRA Life Sciences Inc. is still pre-revenue, so adoption depends on credible validation before wider hospital use.
- Early adopters of novel imaging tech
- Support clinical validation and publications
- Shape protocols and trial design
- Speed broader market acceptance
ENDRA’s Core Buyers: Hospitals, Clinics, and Academic Centers
ENDRA Life Sciences Inc. mainly serves hospitals, radiology groups, hepatology and gastroenterology clinics, and interventional oncology teams. The biggest need is noninvasive liver and procedure imaging, with fatty liver affecting about 30% of adults worldwide and liver disease about 1 in 3 adults. Academic medical centers are early adopters that help validate the platform.
| Segment | Why it buys |
|---|---|
| Hospitals | Workflow and reimbursement |
| Clinics | Repeat liver monitoring |
| Academic centers | Validation and trials |
Cost Structure
Research and development payroll
Research and development payroll is a major cash cost for ENDRA Life Sciences Inc., because engineering, clinical, and management teams must keep a long medtech cycle moving through design, testing, and validation. In medtech, specialized talent is expensive and needed for years, so payroll often becomes the main driver behind product development spend.
Clinical study expenses
Clinical study expenses at ENDRA Life Sciences Inc. cover trials, investigator fees, imaging studies, and patient costs, and they are a key cash outlay because the company must prove safety and performance for adoption and regulatory clearance. These costs usually rise as the pipeline moves forward, since each new study adds sites, scans, and follow-up work.
Regulatory and quality costs
ENDRA Life Sciences Inc. carries ongoing regulatory and quality costs because medical-device work needs full documentation, audits, design controls, and CAPA systems. Legal and IP protection is not one-off either: a U.S. utility patent can run about $320 in filing fees for a large entity, plus maintenance fees at 3.5, 7.5, and 11.5 years, so compliance and patent defense keep cash burn high.
Prototype and supply chain costs
Prototype and supply chain costs for ENDRA Life Sciences Inc. are front-loaded: ultrasound hardware needs parts, contract manufacturing, and testing materials, and each prototype loop can add costly rework before scale lowers unit costs.
Supply chain reliability is a direct cost driver, since late or single-source components can raise build costs and slow development; in 2025, that risk matters more for a small medtech Company with limited production scale.
- Parts and assembly drive early spend
- Prototype rework lifts cash burn
- Supplier delays add cost and risk
Public company overhead
As a Nasdaq-listed development-stage firm, ENDRA Life Sciences Inc. carries public-company overhead for SEC reporting, audit, board governance, finance, and legal work. For small issuers, these general and administrative costs can run in the low millions a year and often absorb a large share of cash burn.
- SEC, audit, and governance fees
- Finance, legal, and corporate ops
- High burden for a small firm
ENDRA's 2025 burn: R&D, regulation, and Nasdaq overhead
ENDRA Life Sciences Inc. cost structure is driven by R&D payroll, clinical validation, and regulatory work, with prototype builds and supplier delays adding more burn. As a small Nasdaq medtech Company, SEC, audit, and governance overhead also stays heavy in 2025.
| Cost | 2025 data |
|---|---|
| U.S. utility patent filing | about $320 |
| Patent maintenance | 3.5, 7.5, 11.5 years |
| Small issuer overhead | low millions yearly |
Revenue Streams
System sales
ENDRA Life Sciences Inc. expects system sales of TAEUS imaging systems to be its main future revenue stream, with customers in hospitals, clinics, and research centers. As of FY2025, the company was still pre-commercial, so capital equipment sales had not yet become a meaningful revenue base, which is typical for diagnostic imaging firms before launch.
Lease and placement models
ENDRA Life Sciences Inc. can place TAEUS systems through lease or placement deals to cut customer upfront capex and speed early adoption. That also creates recurring equipment revenue; as an early-stage company with limited reported sales, even a small installed base can make each new lease more important.
Service contracts
ENDRA Life Sciences Inc. has not yet reported material service-contract revenue in its latest filings, with 2025 revenue still at $0. Once devices are placed, maintenance, repairs, calibration, and software support can add recurring fees and make post-sale cash flow more predictable.
Technology licensing
Technology licensing could let ENDRA Life Sciences Inc. turn its imaging IP into royalty or milestone income from larger medtech partners, without heavy sales spend. This matters if direct commercialization stays slow: many medtech license deals use low- to mid-single-digit royalties, so even a few partner wins can matter more than ENDRA’s current near-zero operating scale.
- Royalty income can be low-cost
- Milestones add cash upfront
- Best if launch timing slips
Research collaboration funding
Research collaboration funding is a key stream for ENDRA Life Sciences Inc., because sponsored R and D can bring in development fees and study support before product sales scale. The General Electric partnership shows how shared work can create paid value, and grants can also fund early-stage testing and validation in FY2025.
- Sponsored R and D payments
- GE partnership example
- Grant-backed early development
ENDRA’s Revenue Still Hangs on Future TAEUS Sales and Early-Stage Funding
ENDRA Life Sciences Inc. had no material revenue in FY2025, so Revenue Streams still depend on future TAEUS system sales, leases, and service contracts. Near-term cash inflows are more likely to come from research collaboration funding, grants, and any licensing or milestone payments.
| Revenue stream | FY2025 status |
|---|---|
| System sales | $0 |
| Services, licensing, grants | Early-stage only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.